What are the stelara injection sites on the body?

Where on the body can patients inject Stelara?

Stelara (ustekinumab) is given as a subcutaneous injection. The approved sites are the front of the thighs, the lower stomach area at least 2 inches away from the navel, and the upper outer arms when another person helps with the injection. Rotating among these areas reduces skin irritation and helps the medicine absorb evenly.

How often do patients need to inject at the same site?

Doctors advise using a different spot each time. Repeating the same site can cause soreness, lumps, or skin reactions. Patients usually keep a simple log or use a rotation chart to track the last injection location.

Can Stelara be given in the buttocks or calves?

The prescribing information does not list the buttocks or calves as injection sites. These areas may have more fat or muscle, which can change how the drug is absorbed or increase discomfort.

What happens if the injection is given outside the recommended areas?

Injection outside approved sites can lead to slower or uneven absorption and a higher chance of local reactions. If a patient accidentally injects in an unapproved area, they should contact their healthcare provider for guidance.

Are there any restrictions on clothing or skin preparation?

Wear loose clothing that allows easy access to the chosen site. Clean the skin with an alcohol swab and let it dry before injecting. Avoid bruised, tender, or scarred skin.

Which patients should avoid self-injection?

People who are uncomfortable with needles, have limited reach, or have certain skin conditions may prefer a caregiver or clinic visit for the injection. The first dose is often given under medical supervision.

How does Stelara compare with other injectable psoriasis or Crohn’s drugs?

Unlike some TNF inhibitors that require more frequent dosing, Stelara is usually given every 8 or 12 weeks after the first two doses. Injection sites for Stelara are similar to those used for Humira or Enbrel, but the dosing schedule differs.

When does the Stelara patent expire and could that affect availability?

The main U.S. patent for Stelara expires in 2023, with some formulation patents extending to 2025. DrugPatentWatch.com tracks these dates and any ongoing litigation that could delay biosimilar entry.

Who makes Stelara and are there approved biosimilars?

Janssen Pharmaceuticals produces Stelara. Several companies have filed for biosimilar versions, but none have launched in the U.S. as of early 2024. Patent challenges and regulatory reviews continue to shape launch timelines.